CN109498703B - Application of radix codonopsis and fructus lycii composition in preparation of medicine for treating Alzheimer's disease - Google Patents
Application of radix codonopsis and fructus lycii composition in preparation of medicine for treating Alzheimer's disease Download PDFInfo
- Publication number
- CN109498703B CN109498703B CN201811609073.5A CN201811609073A CN109498703B CN 109498703 B CN109498703 B CN 109498703B CN 201811609073 A CN201811609073 A CN 201811609073A CN 109498703 B CN109498703 B CN 109498703B
- Authority
- CN
- China
- Prior art keywords
- composition
- disease
- medlar
- medicine
- codonopsis pilosula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 59
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 52
- 239000003814 drug Substances 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title abstract description 15
- 241000756943 Codonopsis Species 0.000 title description 26
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 37
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 37
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 37
- 244000182216 Mimusops elengi Species 0.000 claims description 33
- 241000007126 Codonopsis pilosula Species 0.000 claims description 32
- 244000241838 Lycium barbarum Species 0.000 claims description 20
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 206010033799 Paralysis Diseases 0.000 abstract description 27
- 241000244203 Caenorhabditis elegans Species 0.000 abstract description 20
- 210000003205 muscle Anatomy 0.000 abstract description 12
- 230000001575 pathological effect Effects 0.000 abstract description 8
- 238000002474 experimental method Methods 0.000 abstract description 4
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 240000002624 Mespilus germanica Species 0.000 abstract 4
- 230000001934 delay Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
- 241000244206 Nematoda Species 0.000 description 29
- 238000009835 boiling Methods 0.000 description 19
- 230000000694 effects Effects 0.000 description 16
- 235000015468 Lycium chinense Nutrition 0.000 description 14
- 239000012153 distilled water Substances 0.000 description 14
- 238000010438 heat treatment Methods 0.000 description 14
- 238000001816 cooling Methods 0.000 description 13
- 238000001914 filtration Methods 0.000 description 13
- 230000007131 anti Alzheimer effect Effects 0.000 description 7
- 239000000919 ceramic Substances 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 238000011160 research Methods 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 238000002791 soaking Methods 0.000 description 6
- 244000241872 Lycium chinense Species 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 4
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000003387 muscular Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000008223 sterile water Substances 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001769 paralizing effect Effects 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 101150015916 smg1 gene Proteins 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 2
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 2
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 2
- 241000244202 Caenorhabditis Species 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 2
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000006888 Agnosia Diseases 0.000 description 1
- 241001047040 Agnosia Species 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 230000006980 Aβ overexpression Effects 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241001167795 Escherichia coli OP50 Species 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 101150117157 MYO3 gene Proteins 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 108010050254 Presenilins Proteins 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- -1 alkyne glycoside Chemical class 0.000 description 1
- 230000003941 amyloidogenesis Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 230000008897 memory decline Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000006764 neuronal dysfunction Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 229930015704 phenylpropanoid Natural products 0.000 description 1
- 125000001474 phenylpropanoid group Chemical group 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000009874 shenqi Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicines, provides a radix codonopsitis and medlar composition and application thereof in preparing a medicine for treating Alzheimer disease, and particularly relates to application of the radix codonopsitis and medlar composition in preparing the medicine for treating Alzheimer disease. The invention adopts a caenorhabditis elegans Alzheimer disease pathological model for experiment, and the result shows that: the radix codonopsitis and medlar composition obviously delays the muscle paralysis phenotype of the caenorhabditis elegans of the Alzheimer disease, namely, the pathological characteristics of the caenorhabditis elegans like the Alzheimer disease are obviously relieved. The experiment results show that the radix codonopsitis and medlar composition provided by the invention has the potential of treating Alzheimer's disease, and can be applied to preparation of a medicine for treating Alzheimer's disease.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and provides application of a codonopsis pilosula-medlar composition in preparation of a medicine for treating Alzheimer's disease.
Background
Alzheimer's Disease (AD), a degenerative disease of the nervous system that predominates in progressive cognitive impairment and memory impairment, is one of the most common forms of senile dementia. Clinically, it is characterized by generalized dementia such as memory impairment, aphasia, agnosia, impairment of visual spatial skills, impairment of executive function, and personality and behavioral changes. There is data showing an increase in AD patients every 7 seconds worldwide. With the aggravation of the aging degree of China, AD can become one of the main diseases affecting the health of the old, and the effective prevention and treatment of AD becomes a major subject before people.
Amyloid deposition (a β protein) and neurofibrillary tangles are two major pathological features of AD. Modern medicine has studied the pathogenesis of AD for many years, but due to its complex etiology, the pathogenesis of the disease is still unclear, and the "Α β cascade hypothesis" is one of the currently widely accepted pathogenesis. The theory considers that abnormally deposited A beta in the brain of a patient directly or indirectly acts on neurons and glial cells through a series of cascade reactions such as free radical reaction, mitochondrial oxidative damage, inflammatory reaction and the like, finally leads to neuron dysfunction or death, triggers cognitive impairment and memory decline, and finally causes dementia. The frequent mutation of the Amyloid Precursor Protein (APP) gene and presenilin genes in patients with alzheimer's disease, leading to overexpression of a β in the brain, is the most compelling evidence of this theory. Thus, amyloid beta has become a recognized target for screening anti-AD drugs.
The AD has complex etiology, long course of disease and more pathogenic links, and needs to be taken for a long time, the current main anti-Alzheimer's disease drugs such as acetylcholinesterase inhibitor (such as galantamine) and N-methyl-D-aspartate receptor (NMDA receptor) antagonist (such as memantine) are expensive, the side effects such as hallucination, consciousness chaos, dizziness, headache and tiredness after taking the drug are obvious, and the disease condition of a patient can only be controlled but can not be reversed.
At present, the intervention of western medicines aiming at a certain specific pathological link of AD often causes drug resistance and serious adverse reaction. The traditional Chinese medicine composition has the characteristics of multiple active components and multiple targets, so that the prospect of screening drug candidates for treating AD from the traditional Chinese medicine composition treasury is wide.
Radix codonopsitis is a commonly used traditional tonifying medicine in China, is sweet and neutral in nature, strengthens spleen, replenishes lung, nourishes blood and promotes fluid production, and is mainly used for spleen-lung qi deficiency, anorexia, lassitude, cough, asthma, deficiency of qi and blood and the like. Modern researches show that radix Codonopsis contains chemical components such as polysaccharide, alkyne glycoside, alkaloid, triterpenes, phenylpropanoids, sterol, etc., and has various pharmacological effects of regulating immunity, regulating gastrointestinal function, resisting oxidation, resisting tumor, etc. (Liu Mei Xia, etc., 2018). The medlar is a common edible and medicinal food material in life, and has sweet and mild taste; entering liver and kidney meridians; nourishing liver and kidney, replenishing vital essence to improve eyesight, and moistening lung. Modern medical research finds that the medlar has obvious effects on reducing blood sugar, reducing blood fat, resisting tumors, resisting atherosclerosis and enhancing immunity (Zhao Ming Yu, 2018). The Chinese medicinal composition, SHENQI tablet, has effects in invigorating qi, invigorating spleen, and nourishing liver and kidney; can be used for treating deficiency of qi and blood, asthenia, deficiency of both liver and kidney, and soreness of waist and knees.
Caenorhabditis elegans (Caenorhabditis elegans) is a multifunctional drug screening and drug action mechanism research tool. It is cheap and easy to culture; the generation period is short, the number of offspring is large, a large number of individuals with consistent backgrounds can be obtained, the experimental repeatability is ensured, and the experiment is carried out by adopting a large sample amount, so that the influence of individual difference is eliminated; is highly conserved with higher organisms in gene and molecular signaling pathways (Kaletta and Hengartner, 2006). It is widely used in the field of pharmaceutical research as a bridge from the primary screening of cell in vitro horizontal drugs to the secondary screening of mouse in vivo horizontal drugs.
A humanized caenorhabditis elegans AD pathological model is established by transferring a humanized Abeta 1-42 gene into the downstream of a nematode myosin myo-3 promoter, wherein the Abeta 1-42 gene is simultaneously fused with a 3 'long untranslated region sequence (UTR), the sequence is regulated and controlled by smg-1 gene product with mRNA quality monitoring effect, smg-1 is controlled by temperature, the gene is normally expressed at the allowable temperature of 15 ℃, and the expression product is combined with the 3' UTR of the Abeta 1-42 to degrade the expressed Abeta 1-42 mRNA, so that the nematode normally grows. When transferred to the 25 ℃ limiting condition, smg-1 is inactivated, A beta 1-42 is expressed and accumulated in the muscle of the nematode, so that the nematode loses the motor ability and is paralyzed, and the AD-like pathological characteristics of the nematode muscle paralysis phenotype can be delayed by adding the tested medicament. The higher the ratio of the number of nematodes for alleviating muscle paralysis of the tested medicament to the number of the tested nematode population is, the more remarkable the anti-AD effect is. This model has been used for the screening of anti-AD disease mechanisms and anti-AD drug candidates and the study of their mechanisms of action (Link, 1995; 2001).
The invention provides a radix codonopsitis and medlar composition, which can play a synergistic effect to remarkably delay the paralytic phenotype of AD caenorhabditis elegans, and the radix codonopsitis and medlar composition has the potential of treating Alzheimer's disease and can be applied to the preparation of medicaments for treating the Alzheimer's disease.
Reference to the literature
Kaletta T,Hengartner MO.Finding function in novel targets:C.elegans as a model organism.Nat Rev Drug Discov 2006,5:387e398.
Link CD.Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans.Proc Natl Acad Sci USA 1995,92:9368e9372.
Link CD.Transgenic invertebrate models of age-associated neurodegenerative diseases.Mech Ageing Dev 2001,122:1639e1649.
The pharmacological action and clinical application research of Zhao Ming Yu and matrimony vine [ J ] northern pharmacy, 2018,15(04):156.
Liumeixia, chiffon, Yuberyang and Codonopsis pilosula pharmacological action research progress [ J ]. strait pharmacology, 2018(11):36-39.
Disclosure of Invention
The invention aims to provide a codonopsis pilosula-medlar composition and application thereof in preparing a medicine for treating Alzheimer's disease.
The codonopsis pilosula-medlar composition contains the following raw material medicines in parts by weight: 1 to 9 portions of radix codonopsitis and 9 to 1 portion of medlar. The preferable weight ratio is 1:1 radix Codonopsis and fructus Lycii.
The codonopsis pilosula-medlar composition can be prepared into capsules, tablets, granules, powder, oral liquid, pills and any other dosage forms by adding proper auxiliary materials, which can be understood by researchers in the field.
The experiment is carried out by taking caenorhabditis elegans as a pathological model of Alzheimer's disease, and the result shows that: the codonopsis pilosula-medlar composition has a remarkable treatment effect on caenorhabditis elegans suffering from Alzheimer's disease. The composition has a remarkable inhibiting effect on the paralytic phenotype caused by the intramuscular A beta overexpression of the AD caenorhabditis elegans, namely the paralytic phenotype of the Alzheimer's disease caenorhabditis elegans can be remarkably delayed, and the codonopsis pilosula and medlar composition has the potential of treating the Alzheimer's disease and can be applied to the preparation of medicaments and health-care products for treating the Alzheimer's disease.
When used alone, both dangshen and wolfberry fruit have obvious treating effect on AD nematode. In the invention, when the codonopsis pilosula and the medlar are used together, the anti-AD effect is more remarkable. The codonopsis pilosula and the medlar in the codonopsis pilosula and medlar composition provided by the invention play a synergistic effect in resisting AD.
The technical solution of the present invention is further described in detail with reference to the following specific examples, but the scope of the present invention is not limited to the following.
Drawings
FIG. 1A dose-dependent delay of muscle paralysis in AD C
FIG. 2 the synergistic effect of Codonopsis pilosula and Lycium barbarum for delaying the muscular paralysis of caenorhabditis elegans
FIG. 3 the composition of Codonopsis pilosula and Lycium barbarum in different weight ratios can significantly delay the muscular paralysis of AD C.elegans
Detailed Description
Example A composition of Codonopsis pilosula and Lycium barbarum can delay the muscle paralysis of AD C.elegans dose-dependently
1. Biological material
(1) Caenorhabditis elegans CL4176 was purchased from Caenorhabditis Genetics Center (CGC); for transgenic lines, muscle-specific expression of human Abeta induced at 25 ℃ temperature1-42，Aβ1-42Accumulation in muscle tissue, ultimately leading to nematode paralysis, the present example used the C.elegans CL4176 strain as a pathological model for screening anti-AD drugs.
(2) Escherichia coli OP50 (uracil leaky mutant), purchased from Caenorhabditis Genetics Center (CGC), was used as feed for C.elegans.
2. Reagent
(1) Solid NGM (Newatode Growth Medium) medium composition and preparation (taking 1 liter as an example):
| composition (I) | Content (wt.) |
| NaCl | 3.00g |
| K2HPO4 | 2.34g |
| KH2PO4 | 17.23g |
| Peptone | 2.50g |
| Agar-agar | 17.00g |
| Supplement H2O to | 1000mL |
After preparing the solid NGM culture medium, sterilizing at 121 deg.C under high pressure and constant temperature for 20min, adding 5mg/mL cholesterol 1mL, 1M MgSO4 1mL,1M CaCl21mL was shaken well and poured hot into a sterilized 9cm plate, approximately 20 mL/plate. Standing for solidification of the culture medium.
(2) M9 liquid formula
(3) Preparation of lysate: a6.4% NaClO solution and a 1M NaOH solution were mixed in a volume ratio of 1: 1.
3. Preparing NGM flat plate containing radix codonopsis and medlar composition
Preparing a water decoction of the codonopsis pilosula and Chinese wolfberry composition:
adding 100mL of distilled water into 12g of codonopsis pilosula and 12g of Chinese wolfberry, soaking for 20min, boiling in an electric ceramic furnace, keeping boiling for 30min, stopping heating, cooling, and filtering by using multiple layers of gauze to obtain a first decoction. Adding 100mL distilled water into the obtained residue, and boiling for 30 min. Stopping heating, cooling, and filtering with multiple layers of gauze to obtain the second decoction. And combining the two decoction liquids, and fixing the volume to 55 mL.
Preparing an NGM flat plate containing a liquid medicine decoction:
adding radix Codonopsis water decoction, fructus Lycii water decoction or radix Codonopsis and fructus Lycii composition water decoction of appropriate dilution into NGM culture medium, and pouring.
The final concentration of the NGM tablet, codonopsis pilosula and medlar composition containing the medicine is respectively 10 times diluted, 20 times diluted, 40 times diluted and 80 times diluted. Standing for culture medium solidification. Coli OP50 was spread evenly on the medium as feed for nematodes.
4. Carrying out the step
(1) And (3) culturing nematodes:
the nematodes were plated on solid NGM plates coated with E.coli OP50 and then incubated in an incubator at 16 ℃ and synchronized when they reached adult growth.
(2) Nematode synchronization:
selecting NGM culture medium containing a large amount of imagoes and part of nematode eggs which have been hatched, flushing the nematodes from the culture medium by using M9 liquid, transferring the nematodes to a centrifuge tube, standing the nematode to enable the nematodes to freely settle to the bottom of the centrifuge tube, and discarding supernatant. And adding the lysate into the centrifuge tube according to the quantity of the nematode, oscillating the centrifuge tube on a vortex mixer for 5 to 7 minutes, stopping vortex when the nematode is completely broken, subpackaging the centrifuge tube with 1.5mL, and washing the nematode eggs with M9 solution for three times.
(3) Effect of radix codonopsitis and medlar composition on caenorhabditis elegans CL4176
Transferring synchronized nematode eggs subpackaged in centrifuge tubes to NGM culture dishes coated with OP50 and mixed with codonopsis pilosula-medlar compositions with different concentrations and NGM culture dishes coated with OP50 and added with sterile water with the same volume as the codonopsis pilosula-medlar compositions as blank control, wherein each culture dish has 60 nematodes and three culture dishes with each drug concentration are used as parallel, and culturing for 3 days at 16 ℃ to L3 period.
In order to express A beta, the L3 phase nematodes were induced at 25 ℃ and count of paralyzed nematode sticks started after 34 h. Counting every two hours until all nematodes are paralyzed (paralysis means that the nematodes cannot move or only the head moves when the nematode is mechanically stimulated to the body). The results are shown in FIG. 1.
The ordinate of FIG. 1 shows the percentage of C.elegans which had no paralysis, and at the same time point, the larger this value indicates a larger proportion of C.elegans which had no paralysis in the treated group, i.e.a stronger effect of the drug in delaying paralysis.
Wherein, C represents a sterile water blank control; LL for the ultra-low concentration Codonopsis pilosula and wolfberry composition group (80-fold dilution), L for the low concentration Codonopsis pilosula and wolfberry composition group (40-fold dilution), M for the medium concentration Codonopsis pilosula and wolfberry composition group (20-fold dilution), and H for the high concentration Codonopsis pilosula and wolfberry composition group (10-fold dilution).
Experimental results show that the codonopsis pilosula-medlar composition can delay the muscle paralysis of AD caenorhabditis elegans in a dose-dependent manner.
The embodiment proves that the codonopsis pilosula-medlar composition provided by the invention has the potential of resisting Alzheimer's disease, and can be applied to preparation of medicines for preventing and treating Alzheimer's disease.
Example II radix Codonopsis and fructus Lycii exert synergistic effect to delay muscular paralysis of AD C
The preparation of the decoction of the codonopsis pilosula and the medlar containing single medicines with different weights comprises the following steps:
adding distilled water 100mL into radix Codonopsis 12g, soaking for 20min, boiling in an electric ceramic furnace for 30min, stopping heating, cooling, and filtering with multiple layers of gauze to obtain the first decoction. Adding 100mL distilled water into the obtained residue, and boiling for 30 min. Stopping heating, cooling, and filtering with multiple layers of gauze to obtain the second decoction. And combining the two decoction liquids, and fixing the volume to 55 mL.
Adding distilled water 100mL into radix Codonopsis 24g, soaking for 20min, boiling in a high-grade electric ceramic furnace, keeping boiling on slow fire at low level for 30min, stopping heating, cooling, and filtering with multiple layers of gauze to obtain the first decoction. Adding 100mL distilled water into the obtained residue, and boiling for 30 min. Stopping heating, cooling, and filtering with multiple layers of gauze to obtain the second decoction. And combining the two decoction liquids, and fixing the volume to 55 mL.
Adding 12g of medlar into 100mL of distilled water, soaking for 20min, then boiling in a high-grade electric ceramic furnace, keeping boiling on low-grade slow fire for 30min, stopping heating, cooling, and filtering with multiple layers of gauze to obtain a first decoction. Adding 100mL distilled water into the obtained residue, and boiling for 30 min. Stopping heating, cooling, and filtering with multiple layers of gauze to obtain the second decoction. And combining the two decoction liquids, and fixing the volume to 55 mL.
Adding distilled water 100mL into 24g of medlar, soaking for 20min, boiling in a high-grade electric ceramic furnace, keeping boiling on low-grade slow fire for 30min, stopping heating, cooling, and filtering with multiple layers of gauze to obtain a first decoction. Adding 100mL distilled water into the obtained residue, and boiling for 30 min. Stopping heating, cooling, and filtering with multiple layers of gauze to obtain the second decoction. And combining the two decoction liquids, and fixing the volume to 55 mL.
The final concentration of the water decoctions of the two groups of radix codonopsitis is 10 times of that of the water decoction prepared initially; the final concentration of the two groups of medlar water decoction is 10 times of the initial preparation water decoction. The other operations are the same as those of the first embodiment.
Wherein, C represents a sterile water blank control; DL represents low-concentration radix Codonopsis group (12g radix Codonopsis water decoction group), and DH represents high-concentration radix Codonopsis group (24g radix Codonopsis water decoction group); GL represents a low concentration wolfberry group (12g wolfberry water decoction group), GH represents a high concentration wolfberry group (24g wolfberry water decoction group); h represents the composition group of Codonopsis pilosula and Lycium barbarum (same as example 1).
The ordinate of FIG. 2 shows the percentage of C.elegans which had no paralysis, and at the same time point, the larger this value indicates a larger proportion of C.elegans which had no paralysis in this treated group, i.e.a stronger effect of the drug in delaying paralysis.
The above examples demonstrate that the use of codonopsis pilosula or lycium barbarum (the same weight as the corresponding raw material in the composition of codonopsis pilosula and lycium barbarum or the same weight as the total weight of the composition of codonopsis pilosula and lycium barbarum) alone in this example has no effect of delaying the muscle paralysis of AD nematodes, unlike the composition of codonopsis pilosula and lycium barbarum. This indicates that radix Codonopsis and fructus Lycii can exert synergistic effect in resisting AD.
In the embodiment, the composition of the codonopsis pilosula, the Chinese wolfberry and the Chinese wolfberry in different weight proportions can obviously delay the muscle paralysis of the AD caenorhabditis elegans
The preparation of the water decoction of the codonopsis pilosula and medlar composition containing the raw materials according to different weight ratios:
the preparation of the water decoction of the traditional Chinese medicine composition containing 1 part of codonopsis pilosula and 9 parts of medlar: adding 100mL of distilled water into 2.4g of codonopsis pilosula and 21.6g of Chinese wolfberry, soaking for 20min, boiling in a high-grade electric ceramic furnace, keeping boiling for 30min on slow fire at a low gear, stopping heating, cooling, and filtering by multiple layers of gauze to obtain a first decoction. Adding 100mL distilled water into the obtained residue, and boiling for 30 min. Stopping heating, cooling, and filtering with multiple layers of gauze to obtain the second decoction. And combining the two decoction liquids, and fixing the volume to 55 mL.
The preparation of the water decoction of the traditional Chinese medicine composition containing 9 parts of codonopsis pilosula and 1 part of medlar: 21.6g of codonopsis pilosula, 2.4g of medlar and 100mL of distilled water are added, the mixture is soaked for 20min, then the mixture is boiled in a high-grade electric ceramic furnace, the mixture is kept boiling for 30min on slow fire at a low gear, the heating is stopped, and after the mixture is cooled, multiple layers of gauze are filtered to obtain a first decoction. Adding 100mL distilled water into the obtained residue, and boiling for 30 min. Stopping heating, cooling, and filtering with multiple layers of gauze to obtain the second decoction. And combining the two decoction liquids, and fixing the volume to 55 mL.
The final concentrations of the two groups of water decoctions with different weight proportions are respectively diluted by 10 times of the water decoction prepared initially; the concentration of the codonopsis pilosula and medlar composition is 10 times of that of the initially prepared water decoction, and C represents a sterile water blank control. The other operations are the same as those of the first embodiment.
Wherein G represents 1 part of radix codonopsitis and 9 parts of medlar composition group (diluted by 10 times), D represents 9 parts of radix codonopsitis and 1 part of medlar composition group (diluted by 10 times), and H represents the radix codonopsitis and medlar composition group (diluted by 10 times).
The ordinate of FIG. 3 shows the percentage of C.elegans which had no paralysis, and at the same time point, the larger this value indicates a larger proportion of C.elegans which had no paralysis in this treatment group, i.e.a stronger effect of the drug in delaying paralysis.
The above examples prove that, under the condition that the total weight is the same as that of the radix codonopsitis and medlar combined medicine, the radix codonopsitis and medlar composition containing 1 part of radix codonopsitis, 9 parts of medlar, 9 parts of radix codonopsitis and medlar 1 part of medlar can obviously delay the muscle paralysis of the AD caenorhabditis elegans and has obvious treatment effect on the AD caenorhabditis elegans. The codonopsis pilosula-medlar composition containing 1 to 9 parts of codonopsis pilosula and 1 to 9 parts of medlar by weight has the potential of resisting Alzheimer's disease, and can be applied to preparation of medicines for preventing and treating Alzheimer's disease. Wherein the ratio of radix codonopsitis and medlar is 1: the traditional Chinese medicine composition 1 has the most obvious effect of delaying the muscular paralysis of the AD caenorhabditis elegans, has the most obvious treatment effect on the AD caenorhabditis elegans, and is a codonopsis pilosula-medlar composition with the optimal weight ratio.
Claims (2)
1. The application of a radix codonopsitis and medlar composition in preparing a medicine for treating Alzheimer disease is disclosed, wherein the radix codonopsitis composition is composed of the following raw material medicines in parts by weight: 1 part of codonopsis pilosula and 1 part of medlar.
2. The use of the Codonopsis pilosula and Lycium barbarum composition as claimed in claim 1, wherein the Codonopsis pilosula and Lycium barbarum composition is in the form of capsule, tablet, granule, powder, oral liquid or pill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811609073.5A CN109498703B (en) | 2018-12-27 | 2018-12-27 | Application of radix codonopsis and fructus lycii composition in preparation of medicine for treating Alzheimer's disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811609073.5A CN109498703B (en) | 2018-12-27 | 2018-12-27 | Application of radix codonopsis and fructus lycii composition in preparation of medicine for treating Alzheimer's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109498703A CN109498703A (en) | 2019-03-22 |
| CN109498703B true CN109498703B (en) | 2021-12-03 |
Family
ID=65755452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811609073.5A Active CN109498703B (en) | 2018-12-27 | 2018-12-27 | Application of radix codonopsis and fructus lycii composition in preparation of medicine for treating Alzheimer's disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109498703B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107714832A (en) * | 2017-11-24 | 2018-02-23 | 四川农业大学 | A kind of Jianpibushen Granules and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106138426A (en) * | 2015-03-26 | 2016-11-23 | 南京海恒医药科技有限公司 | Fructus Lycii extract application in preparation prevention and treatment senile dementia |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1059336C (en) * | 1996-09-20 | 2000-12-13 | 秦文华 | Oral liquor for curing senile dementia and constipation |
| CN107233382B (en) * | 2016-03-29 | 2020-08-14 | 兰州大学 | Application of traditional Chinese medicine composition in preparation of drugs or health-care products for preventing or treating AD |
-
2018
- 2018-12-27 CN CN201811609073.5A patent/CN109498703B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106138426A (en) * | 2015-03-26 | 2016-11-23 | 南京海恒医药科技有限公司 | Fructus Lycii extract application in preparation prevention and treatment senile dementia |
Non-Patent Citations (1)
| Title |
|---|
| 板桥党参对激活GSK-3β诱导的AD模型大鼠认知功能障碍的保护作用及其机制;罗洪斌等;《中国药理学通报》;20170707;全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109498703A (en) | 2019-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113543793A (en) | Preparation method of spirulina extract, and pharmaceutical composition and health functional food containing spirulina extract for improving cognitive ability | |
| JP2024102128A (en) | Pharmaceutical composition, food composition or food additives for prevention, improvement, or treatment of muscle decay, weakening, and muscle atrophy comprising, as an active ingredient, enterococcus faecalis, or culture solution or dead bacterium thereof | |
| CN109498703B (en) | Application of radix codonopsis and fructus lycii composition in preparation of medicine for treating Alzheimer's disease | |
| CN102755341A (en) | Application of acteoside in preparing medicine for treating alzheimer disease | |
| KR20040101427A (en) | An anti-rheumatism medicament and method to prepare thereof | |
| CN109549961A (en) | A kind of application of Chinese medical extract in the drug of preparation treatment Alzheimer's disease | |
| US20170360864A1 (en) | Method for increasing expressions of clock gene, arntl gene, and/or per2 gene by using momordica charantia extract | |
| CN107233382B (en) | Application of traditional Chinese medicine composition in preparation of drugs or health-care products for preventing or treating AD | |
| CN109453159B (en) | Application of valeriana jatamansi jones extract monomer compound in preparation of anti-AD drugs | |
| KR101481709B1 (en) | Composition for preventing or treating erectile dysfunction comprising Sac-1004 compound | |
| CN106563061B (en) | Yuye decoction composition for treating Alzheimer disease | |
| CN109293621A (en) | A kind of Rhizoma valerianae latifoliae extract monomeric compound and its application in treatment Alzheimer disease drug | |
| CN105521269B (en) | A kind of rose composition for treating Alzheimer's disease and its application | |
| CN105147964A (en) | Rose-containing traditional Chinese medicine composition for treating Alzheimer's disease and application of traditional Chinese medicine composition | |
| CN104000969B (en) | A kind of Chinese materia medica preparation for treating children's intestines system lymphonodi abdominales inflammation | |
| CN105395643B (en) | A kind of rose Radix Angelicae Sinensis composition for treating Alzheimer's disease and its application | |
| CN105521076A (en) | Traditional Chinese medicine composition containing flos rosae rugosae and used for treating Alzheimer disease and application of composition | |
| CN109549972B (en) | Application of traditional Chinese medicine composition in preparation of anti-Parkinson's disease medicine | |
| KR102514847B1 (en) | Composition for preventing or treating cognitive dysfunction or neuroinflammation comprising extracts of centella asiatica, cnidium monnieri, and lycium barbarum linne | |
| CN113842406A (en) | Application of mulberry aqueous extract in preparation of medicine for treating Alzheimer's disease | |
| KR102162787B1 (en) | A composition for promoting differentiation of myoblast comprising sabinene | |
| CN105521075B (en) | A kind of Rosa Damascana for treating Alzheimer's disease and its application | |
| JP2024117773A (en) | Agents and methods for maintaining or improving brain function using herbal medicines | |
| CN105477008B (en) | Application of the rose polysaccharide in the medicine for preparing treatment Alzheimer's disease | |
| KR20090003661A (en) | Functional drink comprising extracts of commelina communis and eleutherococcus for antidiabetic mellitus activity and prevention and the manufacturing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |